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Abstract
Purpose—Distance to provider might be an important barrier to timely diagnosis and treatment
for cancer patients who qualify for Medicaid coverage. Whether driving time or driving distance is
a better indicator of travel burden is also of interest.
Methods—Driving distances and times from patient residence to primary care provider were
calculated for 3,917 breast, colorectal (CRC) and lung cancer Medicaid patients in Washington
State from 1997 to 2003 using MapQuest.com. We fitted regression models of stage at diagnosis
and time-to-treatment (number of days between diagnosis and surgery) to test the hypothesis that
travel burden is associated with timely diagnosis and treatment of cancer.
Findings—Later stage at diagnosis for breast cancer Medicaid patients is associated with travel
burden (OR = 1.488 per 100 driving miles, P = .037 and OR = 1.270 per driving hour, P = .016).
Time-to-treatment after diagnosis of CRC is also associated with travel burden (14.57 days per
100 driving miles, P = .002 and 5.86 days per driving hour, P = .018).
Conclusions—Although travel burden is associated with timely diagnosis and treatment for
some types of cancer, we did not find evidence that driving time was, in general, better at
predicting timeliness of cancer diagnosis and treatment than driving distance. More intensive
efforts at early detection of breast cancer and early treatment of CRC for Medicaid patients who
live in remote areas may be needed.
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Low-income populations bear a relatively high burden of travel to primary care providers
(PCP) because they often reside in remote, rural areas and have limited means of
transportation.1,2 In addition, American Indians/Alaska Natives (AI/ANs), many of whom
live on remote reservations, have been shown to be a particularly vulnerable group with
respect to late diagnosis and are of special interest here.3–7
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The burden of travel from a patient’s residence to his or her health care provider can be an
important issue influencing access to preventive and treatment services for cancer. Adverse
outcomes associated with greater distance and/or greater travel time to provider may include
delay in treatment and discontinuity in follow-up care.8 Cancer patients may be at particular
risk, because delays in initiating treatment may result in more advanced and difficult-to-treat
disease or in increased risk of relapse after treatment. Longer distances to treatment facilities
have been associated with decreased likelihood of receiving treatment for breast cancer,9–11
undergoing breast-conserving surgery, and with greater likelihood of later stage of diagnosis
for melanoma and colorectal cancer (CRC).12–15
Most studies that have found associations between distance to provider and cancer diagnosis
or treatment have measured distance by using either straight-line distance or driving distance
based on Geographic Information System (GIS) software.9–15 The results of one study were
based on distances derived from patient surveys.16 Because travel distances do not
necessarily correlate with travel time, we used software tools to test the hypothesis that for
Medicaid populations, including AI/ANs and other vulnerable groups, longer travel times to
PCPs were associated with (1) later stage at cancer diagnosis, (2) less frequent receipt of
recommended surgery for initial cancer treatment, and (3) for those who received
recommended surgery, greater number of days between the date of cancer diagnosis and the
date of surgery.
We further explored whether driving time or driving distance better predicted access to care.
We hypothesized that driving time would be more important than driving distance.
Methods
Study population
The study population consisted of Washington State Medicaid enrollees ages 18–64 who
were diagnosed with breast, lung, or colorectal cancer between January 1, 1997, and
December 31, 2003. Incident cases of cancer among Medicaid enrollees were identified by
linking the Washington State Cancer Registry (WSCR) with Medicaid enrollment files over
the years of interest. The WSCR is a statewide registry of all new cancers, excluding non-
melanoma skin cancers. It has been funded since 1995 through the Centers for Disease
Control and Prevention's National Program of Central Cancer Registries. Because Medicaid
sometimes enrolls low-income individuals shortly after a cancer diagnosis, we included
individuals enrolled at any time between January 1, 1996, and December 31, 2005, who
were either enrolled at the time of diagnosis or enrolled within 6 months after diagnosis. We
included only those individuals (1) whose breast, lung, or colorectal cancers were their first
reported malignancies, (2) for whom cancer stage information was available, and (3) who
had a non-HMO Medicaid claim within 12 months after diagnosis. Such a claim
demonstrated that the patient was using Medicaid benefits and that procedure-level data
were available.
To address possible coding inaccuracies, missing data, and grouping of multiple individuals
under the same insurance record, we used a probabilistic method to match Medicaid and
WSCR databases.17 Linking variables included Social Security number, date of birth,
gender, full name, city, zip code, and race. Each linking variable was evaluated for the
likelihood of the variables agreeing in a correct match and the likelihood of accidental
agreement in an unmatched pair of records, and then a weight was assigned to represent the
informational content contributed by each variable. The weights were used during the
linking process to derive a total score that measured the statistical probability of a match.
Incomplete or questionable matches identified by this method were checked by manual
review.
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Information about patients’ race was available in both the Medicaid and WSCR databases.
Additionally, as part of a Tribal Registry Project, the Northwest Portland Area Indian Health
Board (NPAIHB) regularly links its tribal and health records to the WSCR data to help
identify misclassified AI/AN patients. The NPAIHB is a non-profit tribal advisory
organization comprising 43 federally recognized tribes in Washington, Oregon, and Idaho.
This linkage was updated before matching WSCR data with the Medicaid database. When
we found discrepancies, we classified the patient as AI/AN, if any data source identified the
patient as AI/AN. This process reduced the under-reporting of AI/AN race classification
observed in many analyses using administrative and registry-derived data.
Calculation of travel burden
Travel burden was assessed by using driving time and driving distance according to the
online mapping service MapQuest (http://www.mapquest.com).18 For each patient, travel
burden was measured in terms of the distance between the patient’s residential ZIP code and
the ZIP code of the patient’s PCP.
Patient ZIP code was identified through WSCR data and reflects the patient’s location at the
time of diagnosis. Provider ZIP code was identified through Medicaid claims records.
Provider procedure codes were searched for provider specialties that would indicate a PCP
(general practice, family practice, internal medicine, and clinic). Provider ZIP code was
defined as the location of the PCP specified in the claim filed closest to the time of
diagnosis, searching first in the 12 months before diagnosis and then in the 12 months after
diagnosis.
There are 2 kinds of ZIP codes. A 9-digit ZIP code is a point location nearly identical to the
location of a mailing address. A 5-digit ZIP code is an area that encompasses all 9-digit ZIP
codes that share the same first 5 digits with the 5-digit ZIP code. Nine-digit ZIP codes were
used when available. Five-digit ZIP codes were used in the remaining cases. For some
patients who had only 5-digit ZIP codes, the patient ZIP code and the provider ZIP code
were the same. Rather than assign a distance value of zero in these cases, we used the
average distance between 9-digit patient ZIP codes and 9-digit provider ZIP codes that lie
within the same 5-digit ZIP code.
Stage at diagnosis
The WSCR records 4 possible values for stage at diagnosis: in situ, local, regional, and
distant. To evaluate the association between travel burden and stage at diagnosis, we
dichotomized stage as either local or regional/distant. In situ cases were excluded.
Likelihood of treatment
For all cancers, treatment was defined as surgical resection. Receipt of treatment was
determined through (1) WSCR records of initial treatment and (2) Current Procedural
Terminology (CPT) codes and International Classification of Diseases, 9th Edition (ICD-9)
procedure and diagnosis codes in the Medicaid claims files for the 12 months following each
patient’s diagnosis (Table 1).
Time to first treatment after cancer diagnosis
Time to treatment was defined as the number of days from the date of diagnosis to the date
of first treatment, according to Medicaid records. If the day of the month was missing, the
15th was the assumed date. If this assumption resulted in a negative value for time to
treatment, we defined time to treatment as zero.
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We examined the association between travel burden and (1) stage at diagnosis, (2)
likelihood of surgical treatment, and (3) time to first surgical treatment after diagnosis. We
used multivariable logistic regression models to test the hypotheses that driving time and
distance to PCP are positively associated with stage at diagnosis and with likelihood of
treatment. We calculated odds ratios (ORs). All reported P values are 2-sided. We also used
multivariable linear regression to test the hypothesis that travel burden is associated with
time to first treatment. Because surgery is not always recommended for patients with distant
disease, the likelihood of treatment and time-to-treatment models were restricted to patients
with local or regional disease at diagnosis.
To control for confounding, our final models included age at diagnosis (continuous), gender
(CRC and lung cancer models only), race, ethnicity, and diagnosis year. For the likelihood
of treatment and time-to-treatment models, we also included stage at diagnosis (local or
regional). As many Medicaid clients in the sample did not enroll until after their cancer
diagnosis, we were not able to account for comorbidities that may have been present before
diagnosis as a potential factor influencing time to first treatment. Model fit for the driving
distance and driving time models was assessed by using Akaike’s Information Criterion
(AIC).19 Model fit was compared for each outcome.
Results
We identified 4,413 persons ages 18–64 years who were diagnosed with breast, CRC, or
lung cancer in Washington State during 1997–2003, and who were enrolled in the Medicaid
program at the time of, or shortly after, diagnosis (Table 2). Only 3,917 patients had
complete location and treatment information; missing information was more common
among patients with lung cancer.
Of the 4,413 patients for whom we had Medicaid records, 496 (11%) lacked information on
either patient residence or provider location. The excluded and included patients had nearly
identical distributions for the values of race, ethnicity, surgical treatment, and stage at
diagnosis. Of the remaining 3,917 patients, 274 were missing 9-digit ZIP codes. To 217 of
these patients we assigned the driving distance and time between centroids of available 5-
digit ZIP codes. The remaining 57 patients resided in the same 5-digit ZIP codes as their
PCP’s location. We assigned these patients an average driving distance of 3.02 miles and an
average driving time of 6.45 minutes. These were the average driving distances and times
for patients with 9-digit ZIP codes who lived in the same 5-digit ZIP codes as their PCPs.
Table 2 lists the demographic characteristics of the cohort with complete information. The
mean age was 52.5 years (SD 8.4 years); 66% were female, 83% were white and 5% were
AI/AN. The group with the largest proportion of individuals who received surgery within 12
months of diagnosis was CRC patients (98.6%), followed by breast cancer patients (95.7%)
and lung cancer patients (44.3%). The mean number of days from diagnosis to surgery
among patients who received surgery was 21.4. Patients who received surgery in the same
month that they were diagnosed, but with an unknown day of diagnosis, comprised 35% of
all surgery patients. Driving distance to PCP averaged 19 miles (SD 31.3) and driving time
averaged 27 minutes (SD 35.2). A majority of patients lived within 25 miles and 30 minutes
of their PCP (78% and 74%, respectively); however, nearly 10% lived more than 50 miles
and 60 minutes from their PCP. At 11% and 13%, these percentages were slightly higher for
AI/ANs.
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Travel burden and stage at diagnosis
In multivariate logistic regression analyses, for every hour increase in driving time to PCP,
the odds of a breast cancer patient being diagnosed at a later stage increased by 27 percent
(P = .02) (Table 3). Driving distance to the PCP was also associated with later stage at
diagnosis: for every 100-mile increase in driving distance to the PCP, the odds of a breast
cancer patient being diagnosed at a later stage increased by 49 percent (P = .04). Travel
burden was not significantly associated with later stage at diagnosis for CRC or for lung
cancer patients (CRC: OR = 1.08, P = .67; lung: OR = 1.04, P = .75 using driving time, and
CRC: OR = 1.12, P = .73; lung: OR = 1.09, P = .70 using driving distance). The complete
regression results using driving distance are available from the authors on request.
Other characteristics associated with later stage at breast cancer diagnosis included race
(Asian/Pacific Islander and Black patients had later stage at diagnosis relative to white
patients: OR = 1.74, P = .02 and OR = 1.69, P = .03, respectively) and older age at diagnosis
(OR = 0.99 per year, P = .02). Among breast cancer patients, the model using driving time
achieved a slightly better AIC value than the model using driving distance (1945.051 vs
1946.544).
Travel burden and likelihood of treatment
In multivariate logistic regression analyses, driving time to PCP was not significantly
associated with the likelihood of receiving treatment for breast or lung cancer (OR = 0.93, P
= .75 and OR = 0.99, P = .93, respectively) (Table 4). Similarly, driving distance to PCP
was not significantly associated with the likelihood of treatment for breast or lung cancer
(OR = 0.90, P = .81 and OR = 0.97, P = .90, respectively). Likelihood of treatment for
breast cancer was associated with being Black (OR = 0.25, P < .01). Likelihood of treatment
for lung cancer was associated with AI/AN race (OR = 0.40, P = .04), age (OR = 0.98, P = .
04) and local stage at diagnosis (OR = 8.75, P < .01). Nearly every CRC patient received
surgical treatment within one year of diagnosis, so estimates of the association between
travel burden and likelihood of treatment could not be completed for those patients.
Travel burden and time to first treatment
After we adjusted for socio-demographic characteristics, year of diagnosis, and cancer stage,
we found an association between driving time to PCP and the time to first treatment
following cancer diagnosis for a CRC patient. For every 1-hour increase in driving time,
diagnosis was delayed by 5.9 days (P = .02) (Table 5). For every 100-mile increase in
driving distance to PCP, the time-to-treatment for a CRC patient increased by 14.6 days (P
< .01). Hispanic ethnicity was also associated with time-to-treatment among CRC patients
(time-to-treatment was 16.78 days later among Hispanic patients compared to non-Hispanic
patients; P < .01). Travel burden to PCP was not significantly associated with time-to-
treatment for breast or lung cancer patients (breast: 1.37 days per driving hour, P = .44 and
lung: 0.82 days per driving hour, P = .84; breast: 3.02 days per 100 driving miles, P = .39;
lung: 4.84 days per 100 driving miles, P = .54). Among CRC patients, the model using
driving distance achieved a better AIC value than the model using driving time (4810.871 vs
4815.087).
Discussion
Distance traveled to a PCP influences the use of many cancer care services. To our
knowledge, this is the first study to examine the relationship between travel burden for
primary care and cancer treatment among a Medicaid population. We hypothesized that for
low-income people with cancer, travel distance to their PCP would influence both the
likelihood and the timeliness of receiving initial surgical treatment as well as the stage at
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which the cancer was diagnosed. We found that greater driving distance predicted later stage
at diagnosis for breast cancer patients and greater time-to-treatment after diagnosis for CRC
patients. We did not find a significant association between travel burden to PCP and the
likelihood of receiving treatment for any of the cancer types.
Previous studies have found associations between AI/AN race and later stage at diagnosis
for breast cancer and CRC,3,4 but not for lung cancer.20 After adjusting for travel distance
we did not find significant associations between AI/AN race and stage at diagnosis,
likelihood of treatment, or time-to-treatment for breast cancer or CRC patients; however, we
did find an association between likelihood of treatment and AI/AN race for lung cancer
patients. This suggests that the associations between stage at diagnosis and AI/AN race
found in previous studies may be due in part to travel burden.
Of the 3 types of cancer in this study, breast cancer and CRC are the only types included in
routine screening; however, CRC screening detects many precancerous lesions that are not
classified as incidences of cancer and, once removed, prevent the development of cancer.
This might explain why we found an association between stage at diagnosis and travel
burden for breast cancer but not for the other cancers.
Our findings of an association between race and age at diagnosis and later stage at diagnosis
for breast cancer patients were similar to other studies that have examined distance to
provider and cancer treatment and diagnosis, as were our findings of an association between
Hispanic ethnicity and increased time between diagnosis and initial treatment for CRC. In
previous studies, in addition to travel burden, other factors associated with cancer treatment
and diagnosis included age,9–11,13,14 insurance status,13 race/ethnicity,11,13 Metropolitan
Statistical Area size,12 poverty rate,14 personal financial costs and cancer
characteristics.10,11,16
A second goal of this study was to determine whether driving time did a better job than
driving distance of predicting stage at cancer diagnosis or time to first treatment. For
example, driving time may be a more important factor when considering shorter distances in
dense urban areas. Also, driving time takes into account areas with particularly slow means
of transportation, such as ferries over bodies of water or unimproved rural roads. Time may
also be less disparate than distance for rural and urban patients traveling to cancer treatment
facilities. Both driving time and distance predicted the stage at diagnosis for breast cancer
patients and the time to first treatment for CRC patients. The AIC value was better (ie,
lower) for the breast cancer stage model that used driving time, but it was also better for the
CRC time-to-treatment model that used driving distance. Of the 8 models (3 for stage at
diagnosis, 2 for likelihood of treatment, and 3 for time to first treatment), 5 obtained a lower
AIC value when driving distance was used instead of driving time. In general, we did not
find driving time to be a better predictor of earlier diagnosis or more timely treatment than
driving distance. Therefore, using either measure of travel burden appears to be adequate.
In our models, we used a categorical variable to control for year instead of a linear variable.
This specification allowed for a more flexible functional form at a cost of only 6 degrees of
freedom per model. There was no discernable pattern in the values of the categorical year
variable.
This study has several important limitations. Our findings represent Washington State and
may not be representative of the experience of Medicaid enrollees in other areas. We
measured travel distance and time by using MapQuest.com, which is more accurate than
estimates based on straight-line distances. However, we did not have precise location data
for all patients; specifically most had 9-digit ZIP codes, but 5-digit codes were only
available for a substantial minority of individuals. Using the centroid of a 5-digit code
Scoggins et al. Page 6













provides somewhat less accurate travel time and distance information than the centroid of 9-
digit codes, but we do not believe this had a substantial effect on our estimates. Travel time
and distance were calculated on the assumption that all patients used private automobiles.
Some low-income patients may rely on public transportation, which may have different
travel times or distances than assigned in this study.
Provider ZIP codes available from Medicaid claims records may represent the provider’s
billing ZIP code instead of the ZIP code for the location of service delivery. This
misclassification could be unique to urban locations, which could lead to a misrepresentation
of travel times for urban residents included in the study population. Furthermore, some ZIP
codes (residential or provider) may refer to post office boxes rather to physical street
addresses.
It is possible that some of the patients in our study lived closer to other PCPs than those that
cared for them, but the patients could not access those PCPs because they did not accept
Medicaid enrollees. We did not have general information about available PCPs in the area,
or information about PCPs that accepted Medicaid enrollees (other than those the patients
visited). In practice it is difficult to track availability of PCPs to Medicaid enrollees: PCPs
often make changes to their policies on accepting Medicaid enrollees over time (eg, some
“cap” the number of Medicaid patients they see and some drop all Medicaid enrollees when
payments fall) and also change practice locations. Moreover, even with more than one
available provider, it is not clear that Medicaid enrollees choose PCPs based on distance
alone. The influence of availability of PCPs and patient preferences as a factor determining
driving distance among Medicaid enrollees is an area worthy of future study.
Other studies using administrative data have found that health care claims (eg, Medicare
claims) are reliable for assessing cancer-related treatment, including surgery.21 A study
using linked data from the Ohio Cancer Incidence Surveillance System and Ohio Medicaid
claims to assess breast cancer incidence found that the use of both diagnosis and procedure
codes (as in the present study) contributed to the accuracy of case identification.22 The
completeness of Medicaid claims for surgery is expected to be high because of the financial
incentives associated with billing for surgical procedures; however, differential biases
associated with errors in Medicaid claims could exist (eg, certain providers may be more
likely than others to have inaccuracies in administrative coding), leading to over- or under-
estimation of the association between travel burden, receipt of treatment, and time to first
treatment.
Time to treatment for Medicaid patients may be influenced by the number of physicians
accepting Medicaid patients relative to the number of Medicaid patients needing treatment,
particularly for specialized care. Likewise, time to treatment for Hispanic/Latino patients
might be influenced by the availability of Spanish-speaking practices. We did not have
information as to whether providers accepted Medicaid patients, nor their language
fluencies.
Other variables that were not captured in the claims or WSCR data may be important but
unknown predictors of time to first cancer treatment. We were unable to measure marital
status, an indicator of social support that is relevant to travel, including travel to health care
services. Nor did we include urban or rural location as a covariate, given its association with
travel distance. However, rural locations may contribute additional travel burdens unrelated
to distance, such as an increased burden associated with travel in inclement weather.
Travel time may represent a substantial portion of the total time burden associated with a
cancer diagnosis. In this study we did not examine other time-related factors, such as the
time spent waiting for appointments, the time associated with recovery following surgery, or
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the time spent receiving adjuvant treatments such as chemotherapy or radiation. Because
these treatments usually require multiple visits over a defined period, the impact of travel
distance on their use and completion may be more substantial.
Travel time can be considered a direct cost of cancer treatment that is usually borne solely
by patients and their families. As such, time costs associated with travel are an important
component of the full economic burden of cancer. A recent study used Medicare data to
estimate the patient time costs associated with cancer care, including travel time, time spent
waiting for treatment appointments, and time spent receiving care. Patient time costs for the
initial phase (first 12 months) of cancer care were substantial. For the 3 cancers examined in
the present study, costs were $1,008 for breast, $3,708 for colorectal, and $4,141 for lung.23
Travel may be of particular importance for socioeconomically disadvantaged persons,
because time costs associated with care may strain limited resources, and lower provider
accessibility or transportation barriers may result in longer travel times for low-income
individuals. Future studies could investigate the increased travel burden for cancer patients
who rely on public transportation, such as buses and subways.
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Table 1










44110, 44140–44160, 44204–44208, 44210–44213, 44310, 44320,
44392–44394, 45110–45121, 45123, 45126, 45160–45180, 45308,
45309, 45315, 45320, 45333, 45338, 45339, 45383–45385
ICD-9 45.41–45.49, 45.7, 45.71–45.76, 45.79–45.89, 46.01, 46.03, 46.10–46.24,48.31–48.35, 48.40–48.69
Lung
CPT-4 31640, 31641, 32440–32525, 32520, 32657, 32663, 32999
ICD-9 32.20, 32.28, 32.29, 32.30–32.99
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Table 4
Logistic Regression Models of Receipt of Surgical Resection in the First 12 Months Following Diagnosis
Breast Lung
Variable OR P val OR P val
Travel hours 0.929 .750 0.989 .932
Age 1.016 .347 0.975 .043
Female - - 0.870 .423
Local stage at Dx 1.077 .803 8.748 < .001
Hispanic 2.016 .349 0.486 .252
Race
  White 1.000 - 1.000 -
  AI/AN 1.297 .730 0.402 .044
  Asian/PI 0.573 .285 2.069 .083
  Black 0.247 .001 1.710 .198
  Other 0.259 .306
Diagnosis Year
  1997 1.000 - 1.000 -
  1998 9.355 < .001 1.145 .684
  1999 8.609 < .001 0.900 .749
  2000 13.679 < .001 0.984 .961
  2001 7.835 < .001 1.093 .783
  2002 5.846 < .001 0.865 .666
  2003 12.892 < .001 0.736 .328
AIC 412.949 835.374
Note: Figures in bold are statistically significant at the 5% level.
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